drugset / Trial / NCT04528199
[18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer
Phase 1
Terminated
8 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
FutureChem · collab
NaSingle-groupOpen-labelDiagnostic
Summary
The study is an open label, single-arm study designed to evaluate the safety and diagnostic performance of \[18F\]FLOR (FC303) PET/CT imaging to determine the presence or absence of metastatic prostate cancer. .
Timeline
- Start
- 2021-02-01
- Primary completion
- 2023-04-21
- Completion
- 2023-04-21
Outcome
Outcome not reported
Stopped: “The Principal Investigator decided to terminate the study because the PI left Hopkins.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | [18F]FLOR | Diagnostic / imaging agent | 370 mbq | — |